DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Chan A, Delaloge S, Holmes FA. et al.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol 2016;
17: 367-377
doi:10.1016/S1470-2045(15)00551-3
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.